Clene Inc Stock Current Asset
| CLNN Stock | USD 3.54 0.05 1.43% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Clene's long-term financial health and intrinsic value.
As of the 31st of July 2025, Non Current Assets Total is likely to grow to about 12.1 M, while Other Current Assets are likely to drop about 2.6 M. Clene | Current Asset | Build AI portfolio with Clene Stock |
Clene Inc Company Current Asset Analysis
Clene's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Clene Current Asset Historical Pattern
Today, most investors in Clene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Clene's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Clene current asset as a starting point in their analysis.
Clene Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Clene Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Clene Inc has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Clene Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clene's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clene could also be used in its relative valuation, which is a method of valuing Clene by comparing valuation metrics of similar companies.Clene is currently under evaluation in current asset category among its peers.
Clene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Clene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Clene's managers, analysts, and investors.Environmental | Governance | Social |
Clene Fundamentals
| Return On Equity | -17.38 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (50.32) % | ||||
| Current Valuation | 42.46 M | ||||
| Shares Outstanding | 8.98 M | ||||
| Shares Owned By Insiders | 34.60 % | ||||
| Shares Owned By Institutions | 17.22 % | ||||
| Number Of Shares Shorted | 237.78 K | ||||
| Price To Earning | 4.09 X | ||||
| Price To Book | 7.83 X | ||||
| Price To Sales | 89.57 X | ||||
| Revenue | 342 K | ||||
| Gross Profit | 276 K | ||||
| EBITDA | (33.69 M) | ||||
| Net Income | (39.4 M) | ||||
| Cash And Equivalents | 16.23 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 20.84 M | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | (0.57) X | ||||
| Cash Flow From Operations | (21.33 M) | ||||
| Short Ratio | 4.17 X | ||||
| Earnings Per Share | (4.03) X | ||||
| Target Price | 27.83 | ||||
| Number Of Employees | 75 | ||||
| Beta | 0.55 | ||||
| Market Capitalization | 31.35 M | ||||
| Total Asset | 27.34 M | ||||
| Retained Earnings | (282.12 M) | ||||
| Working Capital | 5.87 M | ||||
| Net Asset | 27.34 M |
About Clene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clene Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clene Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Clene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clene will appreciate offsetting losses from the drop in the long position's value.Moving together with Clene Stock
| 0.61 | A | Agilent Technologies Earnings Call Today | PairCorr |
Moving against Clene Stock
| 0.64 | DRMA | Dermata Therapeutics | PairCorr |
| 0.63 | VRAX | Virax Biolabs Group | PairCorr |
| 0.58 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.54 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.54 | DYAI | Dyadic International Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Clene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clene Inc to buy it.
The correlation of Clene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clene Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Clene Piotroski F Score and Clene Altman Z Score analysis. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clene. If investors know Clene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.614 | Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth 0.11 | Return On Assets |
The market value of Clene Inc is measured differently than its book value, which is the value of Clene that is recorded on the company's balance sheet. Investors also form their own opinion of Clene's value that differs from its market value or its book value, called intrinsic value, which is Clene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clene's market value can be influenced by many factors that don't directly affect Clene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.